Gsa Capital Partners LLP Wave Life Sciences Ltd. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

A detailed history of Gsa Capital Partners LLP transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 63,513 shares of WVE stock, worth $762,156. This represents 0.04% of its overall portfolio holdings.

Number of Shares

63,513

Previous 55,258 14.94%

Holding current value

$762,156

Previous $276,000 88.77%

% of portfolio

0.04%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$5.12 - $9.01 $42,265 - $74,377	8,255 Added 14.94%	63,513 $521,000
Q2 2024 Aug 15, 2024	SELL	$4.38 - $6.48 $174,232 - $257,767	-39,779 Reduced 41.86%	55,258 $276,000
Q1 2024 May 03, 2024	BUY	$3.54 - $6.84 $336,430 - $650,053	95,037 New	95,037 $586,000
Q2 2023 Aug 14, 2023	BUY	$3.51 - $4.69 $292,067 - $390,254	83,210 New	83,210 $302,000
Q2 2022 Aug 09, 2022	SELL	$1.23 - $3.25 $242,171 - $639,882	-196,887 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.0 - $3.28 $46,484 - $76,233	23,242 Added 13.38%	196,887 $394,000
Q4 2021 Feb 14, 2022	BUY	$3.14 - $5.15 $442,350 - $725,511	140,876 Added 429.91%	173,645 $545,000
Q3 2021 Nov 12, 2021	BUY	$4.89 - $7.12 $160,240 - $233,315	32,769 New	32,769 $161,000
Q4 2018 Feb 12, 2019	SELL	$37.1 - $50.11 $281,960 - $380,836	-7,600 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$36.35 - $55.2 $69,065 - $104,880	-1,900 Reduced 20.0%	7,600 $380,000
Q2 2018 Aug 09, 2018	SELL	$33.85 - $50.65 $358,810 - $536,890	-10,600 Reduced 52.74%	9,500 $363,000
Q1 2018 May 11, 2018	BUY	$32.45 - $54.7 $298,540 - $503,240	9,200 Added 84.4%	20,100 $806,000
Q4 2017 Feb 14, 2018	BUY	$21.8 - $39.35 $237,620 - $428,915	10,900	10,900 $383,000

Others Institutions Holding WVE

# of Institutions

166

Shares Held

117M

Call Options Held

148K

Put Options Held

109K

View Full List

About Wave Life Sciences Ltd.

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $1.04B
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

More about WVE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Wave Life Sciences Ltd. Transaction History